Elicera Therapeutics AB (publ) (ELIC.ST)

SEK 1.71

(-0.29%)

Market Cap (In SEK)

60 Million

Revenue (In SEK)

11.23 Million

Net Income (In SEK)

-16.39 Million

Avg. Volume

409.64 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.852-5.68
PE
-
EPS
-
Beta Value
-0.424
ISIN
SE0015382080
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jamal El-Mosleh M.Sc.
Employee Count
-
Website
https://www.elicera.com
Ipo Date
2021-06-11
Details
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.